Commentary: Bringing new drugs to market is already expensive and time-consuming. Undercutting the FDA will only make it harder. https://www.japantimes.co.jp/opinion/2023/04/19/commentary/world-commentary/abortion-pill/?utm_content=buffer6a60d&utm_medium=social&utm_source=bufferapp.com&utm_campaign=buffer #opinion #commentary #abortion #fda #womensissues #mifepristone
Follow
@thejapantimes But they're not undercutting the FDA. They're grappling with the FDA running afoul of its own standards.
The courts in this case are trying to figure out how to deal with an FDA that undercut itself, looking at the FDA's own records of dubious approval to sort out what to do now.
